Soc. Generale Call 50 SDZ 20.06.2.../ DE000SY6DWQ0 /
| 12/11/2024 08:38:10 | Var.-0.011 | Denaro22:00:39 | Lettera22:00:39 | Sottostante | Prezzo di esercizio | Expiration date | Tipo di opzione |
|---|---|---|---|---|---|---|---|
| 0.089EUR | -11.00% | - Quantità in denaro: - |
- Quantità in lettera: - |
SANDOZ GROUP N | 50.00 CHF | 20/06/2025 | Call |
GlobeNewswire
12/08
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar po...
GlobeNewswire
25/07
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory dise...
GlobeNewswire
01/07
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
GlobeNewswire
22/05
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...
GlobeNewswire
30/04
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of San...
GlobeNewswire
30/04
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire
22/04
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immun...
GlobeNewswire
21/03
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for l...
GlobeNewswire
04/03
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leader...
GlobeNewswire
29/02
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser ...
GlobeNewswire
31/01
Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
GlobeNewswire
22/01
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US m...
GlobeNewswire
21/11/2023
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve pa...
